Rankings
▼
Calendar
AKBA Q1 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$52M
-40.9% YoY
Gross Profit
$18M
33.8% margin
Operating Income
-$65M
-124.2% margin
Net Income
-$70M
-133.0% margin
EPS (Diluted)
$-0.45
QoQ Revenue Growth
-7.8%
Cash Flow
Operating Cash Flow
-$71M
Free Cash Flow
-$71M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$629M
Total Liabilities
$415M
Stockholders' Equity
$214M
Cash & Equivalents
$253M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$52M
$88M
-40.9%
Gross Profit
$18M
$61M
-70.9%
Operating Income
-$65M
-$59M
-9.8%
Net Income
-$70M
-$61M
-14.5%
Revenue Segments
Product
$30M
58%
License Collaboration And Other Revenue
$22M
42%
← FY 2021
All Quarters
Q2 2021 →